An innate IL-25-ILC2-MDSC axis creates a cancer-permissive microenvironment for


Journal

Science immunology
ISSN: 2470-9468
Titre abrégé: Sci Immunol
Pays: United States
ID NLM: 101688624

Informations de publication

Date de publication:
03 06 2022
Historique:
entrez: 3 6 2022
pubmed: 4 6 2022
medline: 9 6 2022
Statut: ppublish

Résumé

Interleukin-25 (IL-25) and group 2 innate lymphoid cells (ILC2s) defend the host against intestinal helminth infection and are associated with inappropriate allergic reactions. IL-33-activated ILC2s were previously found to augment protective tissue-specific pancreatic cancer immunity. Here, we showed that intestinal IL-25-activated ILC2s created an innate cancer-permissive microenvironment. Colorectal cancer (CRC) patients with higher tumor

Identifiants

pubmed: 35658010
doi: 10.1126/sciimmunol.abn0175
pmc: PMC7612821
mid: EMS144798
doi:

Substances chimiques

APC protein, human 0
Adenomatous Polyposis Coli Protein 0
Interleukin-17 0
Interleukin-33 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

eabn0175

Subventions

Organisme : Wellcome Trust
ID : 100963
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 220223
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U105178805
Pays : United Kingdom
Organisme : MRF
ID : MRF_MRF-104-0013-S-MCKEN-C0902
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Références

Sci Rep. 2019 May 2;9(1):6833
pubmed: 31048714
PLoS Med. 2013;10(5):e1001453
pubmed: 23700391
Gastroenterology. 2009 Jun;136(7):2204-2213.e1-13
pubmed: 19248780
Nat Immunol. 2018 Oct;19(10):1093-1099
pubmed: 30201992
Immunity. 2014 Dec 18;41(6):947-59
pubmed: 25500368
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Sci Immunol. 2020 Jan 10;5(43):
pubmed: 31924686
Immunity. 2001 Nov;15(5):763-74
pubmed: 11728338
Sci Transl Med. 2015 Jul 29;7(298):298ra117
pubmed: 26223300
Cell Res. 2020 Jul;30(7):610-622
pubmed: 32367039
Proc Natl Acad Sci U S A. 2015 May 12;112(19):E2487-96
pubmed: 25918379
Ann Trop Med Parasitol. 2005 Jan;99(1):47-52
pubmed: 15701255
Nature. 2010 Apr 29;464(7293):1367-70
pubmed: 20200518
J Exp Med. 2006 Apr 17;203(4):1105-16
pubmed: 16606668
Cancer Lett. 2021 Apr 1;502:34-43
pubmed: 33429004
Immunity. 2014 Aug 21;41(2):283-95
pubmed: 25088770
BMC Bioinformatics. 2013 Apr 15;14:128
pubmed: 23586463
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Cancer Res. 2004 Feb 1;64(3):1130-9
pubmed: 14871848
Cancer Res. 2015 Nov 1;75(21):4483-93
pubmed: 26432403
Nat Immunol. 2021 Jul;22(7):851-864
pubmed: 34099918
Int J Exp Pathol. 2008 Dec;89(6):466-75
pubmed: 19134056
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Nature. 2020 Mar;579(7797):130-135
pubmed: 32076273
J Pathol. 2016 Jan;238(2):141-51
pubmed: 26414675
Int J Cancer. 2006 Jan 1;118(1):25-34
pubmed: 16049979
J Interferon Cytokine Res. 2015 Apr;35(4):273-80
pubmed: 25383957
Gut. 2020 Dec;69(12):2261-2263
pubmed: 32139551
Eur J Immunol. 2013 Feb;43(2):488-98
pubmed: 23169007
Nat Rev Immunol. 2009 Mar;9(3):162-74
pubmed: 19197294
Sci Rep. 2018 Feb 13;8(1):2924
pubmed: 29440650
Radiat Oncol J. 2020 Mar;38(1):1-10
pubmed: 32229803
Cell. 1990 Jun 1;61(5):759-67
pubmed: 2188735
Immunity. 2010 Mar 26;32(3):426-36
pubmed: 20303297
Oncotarget. 2014 Oct 15;5(19):9269-80
pubmed: 25211188
Nat Med. 2013 Jan;19(1):57-64
pubmed: 23202296
Sci Rep. 2016 May 11;6:25643
pubmed: 27165713
Curr Protoc. 2021 Mar;1(3):e90
pubmed: 33780170
Cancer Invest. 2010 Jan;28(1):38-43
pubmed: 20001295
Cancer Res. 2000 Sep 15;60(18):5040-4
pubmed: 11016626
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Gastroenterology. 2016 Aug;151(2):278-287.e6
pubmed: 27063727
Cancer Res. 2014 Aug 15;74(16):4258-69
pubmed: 24906621
Nature. 2016 Jan 14;529(7585):221-5
pubmed: 26675736
Sci Rep. 2017 Dec;7(1):25
pubmed: 28154415
Cancer Immunol Immunother. 2020 Jul;69(7):1279-1292
pubmed: 32185408
Exp Clin Immunogenet. 1987;4(3):144-52
pubmed: 2856203
Front Immunol. 2018 Jun 06;9:1271
pubmed: 29928279
Gut. 2005 Jul;54(7):1034-43
pubmed: 15951555
Carcinogenesis. 2011 Sep;32(9):1333-9
pubmed: 21730361
Adv Exp Med Biol. 2009;656:85-106
pubmed: 19928355
Front Immunol. 2018 Jun 11;9:1310
pubmed: 29942309
Pathol Res Pract. 2000;196(12):807-15
pubmed: 11156321
J Allergy Clin Immunol. 2012 Jan;129(1):191-8.e1-4
pubmed: 22079492
Adv Exp Med Biol. 2017;1036:105-128
pubmed: 29275468
Sci Immunol. 2018 Mar 2;3(21):
pubmed: 29500225
Cell Rep Med. 2021 Jul 27;2(8):100353
pubmed: 34467243
Adv Immunol. 2000;74:181-273
pubmed: 10605607
Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):E2357-E2364
pubmed: 28270604
Sci Rep. 2015 Oct 14;5:15179
pubmed: 26462617
Cancer Res. 2010 Jan 15;70(2):792-801
pubmed: 20068187
Nat Immunol. 2020 Sep;21(9):998-1009
pubmed: 32747815
Biomed Pharmacother. 2018 Jul;103:301-307
pubmed: 29656186
J Clin Oncol. 2009 Dec 10;27(35):5944-51
pubmed: 19858404
Cancers (Basel). 2021 Feb 01;13(3):
pubmed: 33535624
Cell. 2021 Sep 16;184(19):5015-5030.e16
pubmed: 34407392
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
J Innate Immun. 2012;4(1):31-40
pubmed: 21912088
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
World J Surg Oncol. 2020 Jul 1;18(1):149
pubmed: 32611359
Gastroenterology. 2016 Apr;150(4):931-43
pubmed: 26764183
Immunity. 2014 Mar 20;40(3):425-35
pubmed: 24613091
Sci Rep. 2017 Jul 14;7(1):5520
pubmed: 28710436

Auteurs

Eric Jou (E)

MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.

Noe Rodriguez-Rodriguez (N)

MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.

Ana-Carolina F Ferreira (AF)

MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.

Helen E Jolin (HE)

MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.

Paula A Clark (PA)

MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.

Kovilen Sawmynaden (K)

LifeArc, SBC Innovation Campus, Stevenage SG1 2FX, UK.

Michelle Ko (M)

MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.

Jane E Murphy (JE)

MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.

Jonathan Mannion (J)

MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.

Christopher Ward (C)

Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Cambridge CB2 0AW, UK.

David J Matthews (DJ)

LifeArc, SBC Innovation Campus, Stevenage SG1 2FX, UK.

Simon J A Buczacki (SJA)

Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Cambridge CB2 0AW, UK.

Andrew N J McKenzie (ANJ)

MRC Laboratory of Molecular Biology, Cambridge CB2 0QH, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH